

TARGETING apoptosis

CLINICAL TRIALS

Tuesday, 20 December 2022

Starhotel Excelsior, BOLOGNA

Chairs: G. Marconi, G. Martinelli, C. Papayannidis

Co-Chairs: C. Cerchione, A. Curti, A. Lucchesi,
G. Musuraca, G. Simonetti

08.30 I SESSION

AVALON Clinical trials, targeting apoptosis

Moderators: G. Martinelli, A. Venditti

08.40 The experience of the AVALON study:
from enrollment to data analysis

C. Zingaretti – E. Petracchi

09.00 AVALON: Venetoclax in R/R patients

G. Marconi

09.15 AVALON: Venetoclax in combination with HMA
in elderly and unfit newly diagnosed patients

C. Papayannidis

09.30 "Inside the clinical trial": raccomandazioni for
the correct use of VEN-AZA in AML patients

G. Martinelli

09.45 MRD and molecular/correlative studies on
VENETOCLAX treatment patients

G. Simonetti

10.00 The ultra unfit and the ultra aged AML patients

N.S. Fracchiolla

10.15 General Discussion

10.30 Coffee Break

11.00 II SESSION

Gimema Clinical trials, V-FLAI - Propensity Score V-Flai vs AML1310

Moderators:

E. Audisio, G. Martinelli, A. Piciocchi, A. Venditti

11.00 V-Flai: UPDATE from the ASH presentation

G. Marconi

11.15 Propensity Score V-Flai vs AML1310:

news post ASH and how to move forward

A. Piciocchi

11.30 Venetoclax plus Aza in NPM1 R/R
patients: The Gimema 2521 trial

A. Curti

11.45 V-FLAI MRD assesment

R. Lemoli

12.00 General Discussion

12.15 Reduced V-FLAI and G-CSF use for
elderly patients?

E. Audisio

12.30 How to manage infection in
Venetoclax treated AML patients

C. Minotti

12.45 How I Manage neutropenia in
Venetoclax treated patients

S. Capria – S. Trisolini

13.00 Ketogenic diet plus Fludarabine
(Diet-V-Flai) for by pass Venetoclax
resistance in RAS mutated AML?

G. Martinelli

13.15 Italian Registry for IDH1 mutated
AML: report of activity

M. Messina

13.30 NGS panel for a better
characterization of myelomas with
translocations?

C. Terragna

Discussion

Farewell Christmas Light Lunch

